Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | ENZAMET correlative analysis: enzalutamide overcomes poor prognosis in BRCA-mutated mHSPC

Anis Hamid • 30 May 2026
ASCO 2026
Genitourinary Cancer Prostate Cancer ADT Enzalutamide
ENZAMET

Anis Hamid, MBBS, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of a correlative study of the Phase III ENZAMET trial (NCT02446405), which investigated germline genetic correlates in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus non-steroidal anti-androgen or enzalutamide. The study found a clear prognostic effect of germline BRCA mutations, with patients having a shorter progression-free survival (PFS) in the control arm, and that this effect was neutralized by the addition of enzalutamide. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Anis Hamid

Insights from germline and multimodal data: can biomarkers guide first-line therapy in mHSPC?
1:07
Insights from germline and multimodal data: can biomarkers guide first-line therapy in mHSPC?
Anis Hamid • 31 May 2026
How far away are we from implementing CTC-based approaches in prostate cancer?
1:30
How far away are we from implementing CTC-based approaches in prostate cancer?
Anis Hamid • 6 Jun 2022
Remaining questions on PSMA PET imaging in prostate cancer
1:26
Remaining questions on PSMA PET imaging in prostate cancer
Anis Hamid • 6 Jun 2022
Elucidating biomarkers of prognosis of 177Lu-PSMA-617-based therapy
3:25
Elucidating biomarkers of prognosis of 177Lu-PSMA-617-based therapy
Anis Hamid • 6 Jun 2022

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals